HK, Lucence collaborate for early lung cancer detection

Lung cancer was the most common cancer in Hong Kong.

Hong Kong Precision Oncology Society (HKPOS) will collaborate with Lucence, a precision oncology company, to evaluate a blood test for early lung cancer detection—the first in Hong Kong.

Lung cancer was the most common cancer in Hong Kong, with 5,707 new cases and 3,782 deaths. More than half of the patients were diagnosed at late-stage IV, and the 5-year survival rate was as low as 10%.

The study investigates the sensitivity and specificity of liquid biopsy tests for predicting lung cancer lesions measuring 6-20mm, in comparison to using only low-dose CT scans.

Lucence's liquid biopsy offers a simple, less painful blood draw to sample tumors, potentially improving cancer screening and diagnosis by detecting circulating tumor DNA and RNA.

The two will provide 600 individuals, aged 45 to 74, a CT scan and an advanced liquid biopsy test.